Issue Contents

Pearls and Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis

Styliani Tsiami, Xenofon Baraliakos

Mediterr J Rheumatol 2022;33(Suppl 1):109-14
Molecular Mechanisms of New Bone Formation in Axial Spondyloarthritis

Kalliopi Klavdianou, Anastasia Kanellou, Dimitrios Daoussis

Mediterr J Rheumatol 2022;33(Suppl 1):115-25
Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology

Nikoleta Zioga, Dionysios Kogias, Vasiliki Lampropoulou, Nikolaos Kafalis, Charalampos Papagoras

Mediterr J Rheumatol 2022;33(Suppl 1):126-36
Treat-to-Target in Axial Spondyloarthritis: Are we there yet?

Krystel Aouad, Bassel El-Zorkany

Mediterr J Rheumatol 2022;33(Suppl 1):137-41
Axial Disease in Psoriatic Arthritis: how can we Define it, and does it have an Impact on Treatment?

Clementina Lopez-Medina, Nelly Ziade

Mediterr J Rheumatol 2022;33(Suppl 1):142-9
Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?

Chrysoula G. Gialouri, Gerasimos Evangelatos, George E. Fragoulis

Mediterr J Rheumatol 2022;33(Suppl 1):150-61
Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study

Gkikas Katsifis, Athina Theodoridou, Andreas Bounas, Panagiotis Georgiou, Petros Sfikakis, Kalliopi Fragiadaki, Theodoros Dimitroulas, Evangelia Mole, Lars Bauer, Thomas Kumke, Bengt Hoepken

Mediterr J Rheumatol 2022;33(Suppl 1):162-72

ARCHIVE

Volume 33, March 2022, Supplement 1